Tilray Brands, Inc. (TLRY) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to break-even earnings per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -100%. A quarter ago, it was expected that this company would post a loss of $0.04 per share when it actually produced break-even earnings, delivering a surprise of 100%. Over the last four quarters, the company ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended May 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38594 TILRAY BRANDS, INC. (Exact name of Registrant as specified in its Charter) Delaware 82-4310622 (State or other jurisdiction of incor ...

Fiscal 2024 Net Revenue Reaches $789 Million, Led by Cannabis Net Revenue of $273 Million and Beverage-Alcohol Net Revenue of $202 Million Tilray Brands, Inc. ("Tilray") (Nasdaq: TLRY; TSX: TLRY), is a leading global lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America that is leading as a transformative force at the nexus of cannabis, beverage, wellness, and entertainment, elevating lives through moments of connection. Tilray's mis ...

Record Fiscal 2024 Gross Profit Fiscal 2024 Net Revenue Reaches $789 Million, Led by Cannabis Net Revenue of $273 Million and BeverageAlcohol Net Revenue of $202 Million Irwin D. Simon, Chairman and Chief Executive Officer, stated, "Tilray Brands is leading the convergence of cannabis, beverages, and wellness on a global scale. In Fiscal 2024, the Company achieved remarkable growth across its businesses, with a 26% increase in net revenue over the prior year, record-breaking performance in gross profit and ...

Record Fiscal 2024 Gross Profit Fiscal 2024 Net Revenue Reaches $789 Million, Led by Cannabis Net Revenue of $273 Million and BeverageAlcohol Net Revenue of $202 Million NEW YORK and LEAMINGTON, Ontario, and NEÜMUNSTER, Germany, July 29, 2024 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray", "our", "we" or the "Company") (Nasdaq: TLRY; TSX: TLRY), a global lifestyle consumer packaged goods company elevating lives through moments of connection, today reported financial results for its fourth quarter and fis ...

TLRY stock also isn't seeing much movement today with a slight gain as of Monday afternoon. Tilray (NASDAQ:TLRY) stock is on the move Monday as investors in the cannabis company react to it securing a trading license in Germany for its Aphria RX subsidiary. Denise Faltischek, Chief Strategy Officer and Head of International at Tilray, said this about the news. Despite the additional license in Germany, TLRY stock isn't seeing much trading today. As of this writing, only about 12 million shares have changed ...

NEUMÜNSTER, Germany, July 29, 2024 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray") (NASDAQ:TLRY, TSX:TLRY), a global leader in medical cannabis research, cultivation, production, and distribution, today announced that Aphria RX GmbH ("Aphria RX") has received a trading license, which will allow it to sell and distribute a broad range of medical cannabis products to pharmacies, hospitals, and medical wholesalers throughout Germany. As a leading and trusted medical cannabis company, Tilray strongly believe ...

Tilray Brands Performance and Market Position - Tilray Brands is preparing to announce its Q4 2024 earnings, with investors closely monitoring its performance and strategic direction [1] - The company faces challenges from high excise taxes and price compression in Canada, which have significantly impacted profit margins [2] - Tilray's net revenues are expected to increase by 22.5% year-over-year to $225.7 million in Q4, with a consensus estimate of a loss of 2 cents per share [12] - The company has a trailing four-quarter earnings surprise of 50%, with a 100% margin in the last reported quarter [13] Industry and Regulatory Environment - The cannabis industry is subject to significant regulatory uncertainties and market risks, despite favorable legalization trends [2] - Potential regulatory changes, such as the transition to an Ad Valorem Tax system, could significantly enhance Tilray's profitability [16] - Legislative reforms in Europe, including the removal of medical cannabis from narcotics acts, are expected to boost market penetration [17] Tilray's Strategic Initiatives and Market Reach - Tilray's diversified product innovation, including medical cannabis formats, THC-infused beverages, and pharmaceutical-grade medicines, enhances its ability to capture new market segments globally [14] - The company's focus on organic growth and strategic acquisitions, such as the integration of HEXO and Truss Beverage, underscores its commitment to maximizing revenue opportunities [14] - Tilray has an extensive geographic reach, with 62% of net revenues generated in North America, 36% in EMEA, and 2% from other regions, reducing market risk and leveraging opportunities in different economic environments [15] - In Europe, Tilray maintains a leading position in the medical cannabis market, particularly in Germany, where it holds the highest revenue market share [17] Earnings and Stock Performance Insights - Tilray Brands currently has a Zacks Rank 3 but an Earnings ESP of 0.00%, making an earnings surprise prediction difficult [4] - The Zacks model does not conclusively predict an earnings beat for Tilray this time, despite its Zacks Rank 3 [3] Alternative Investment Opportunities - Chewy, Inc (CHWY) has an Earnings ESP of +1.61% and a Zacks Rank of 1, with expected quarterly revenues of $2.86 billion, a 2.9% year-over-year increase, and earnings per share of 22 cents, up 46.7% from the year-ago quarter [5][6] - Ollie's Bargain (OLLI) has an Earnings ESP of +2.38% and a Zacks Rank of 1, with expected quarterly revenues of $562.4 million, a 9.3% year-over-year increase, and earnings per share of 78 cents, up 16.4% from the year-ago quarter [7][8] - Costco Wholesale Corporation (COST) has an Earnings ESP of +1.23% and a Zacks Rank of 2, with expected quarterly revenues of $80 billion, a 1.3% year-over-year increase, and earnings per share of $5.02, up 3.3% from the year-ago quarter [9][10]

Company Milestones - Tilray Brands, Inc announced the approval of its new medical cannabis extract, Tilray Oral Solution THC10:CBD10, in Portugal, marking another milestone in its European medical cannabis operations [11] - This approval follows the earlier approval of Tilray Medical whole flower THC 18 and the first cannabis extract in Portugal earlier this year [11] Product Portfolio and Market Expansion - Tilray Medical offers a diverse portfolio of EU-GMP certified medicinal cannabis products, including Tilray, Aphria, Broken Coast, Symbios, and Navcora brands [12] - The company operates in over 20 countries across five continents, supplying medical cannabis to patients, physicians, hospitals, pharmacies, researchers, and governments [12] - Tilray Medical has expanded its medical cannabis offerings in Portugal with the approval of Tilray Solução Oral THC10:CBD10, aimed at addressing specific medical conditions [1] Global Operations and Leadership - Tilray Brands, Inc is a global leader in cannabis research, cultivation, production, and distribution, with operations in Canada, the United States, Europe, Australia, and Latin America [6] - The company supports over 20 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and craft beverages [6] - Tilray Medical is one of the largest suppliers of medical cannabis brands globally, with a focus on safe and reliable access for patients [12] Strategic Vision and Mission - Tilray Brands aims to be the most responsible, trusted, and market-leading cannabis consumer products company globally, with a portfolio of innovative and high-quality brands [6] - The company is dedicated to transforming lives and fostering dignity for patients through safe access to medical cannabis products [12]

The most recent trading session ended with Tilray Brands, Inc. (TLRY) standing at $1.89, reflecting a -1.56% shift from the previouse trading day's closing. This change lagged the S&P 500's daily loss of 0.16%. Elsewhere, the Dow lost 0.14%, while the tech-heavy Nasdaq lost 0.06%. The upcoming earnings release of Tilray Brands, Inc. will be of great interest to investors. The company's earnings report is expected on July 29, 2024. Meanwhile, the latest consensus estimate predicts the revenue to be $225.65 m ...